ATE370135T1 - Substituierte piperidine als histamin-h3- rezeptorliganden - Google Patents

Substituierte piperidine als histamin-h3- rezeptorliganden

Info

Publication number
ATE370135T1
ATE370135T1 AT04763339T AT04763339T ATE370135T1 AT E370135 T1 ATE370135 T1 AT E370135T1 AT 04763339 T AT04763339 T AT 04763339T AT 04763339 T AT04763339 T AT 04763339T AT E370135 T1 ATE370135 T1 AT E370135T1
Authority
AT
Austria
Prior art keywords
histamine
receptor ligands
substituted piperidines
piperidines
substituted
Prior art date
Application number
AT04763339T
Other languages
German (de)
English (en)
Inventor
J M Bailey
Gordon Bruton
Anthony Huxley
Peter Henry Milner
B S Orlek
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0316893A external-priority patent/GB0316893D0/en
Priority claimed from GB0411167A external-priority patent/GB0411167D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of ATE370135T1 publication Critical patent/ATE370135T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/16Central respiratory analeptics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/30Drugs for disorders of the nervous system for treating abuse or dependence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/46Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Anesthesiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT04763339T 2003-07-18 2004-07-16 Substituierte piperidine als histamin-h3- rezeptorliganden ATE370135T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0316893A GB0316893D0 (en) 2003-07-18 2003-07-18 Novel compounds
GB0411167A GB0411167D0 (en) 2004-05-19 2004-05-19 Novel compounds

Publications (1)

Publication Number Publication Date
ATE370135T1 true ATE370135T1 (de) 2007-09-15

Family

ID=34137741

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04763339T ATE370135T1 (de) 2003-07-18 2004-07-16 Substituierte piperidine als histamin-h3- rezeptorliganden

Country Status (9)

Country Link
US (1) US20060247227A1 (OSRAM)
EP (1) EP1646620B1 (OSRAM)
JP (1) JP2006528147A (OSRAM)
AR (1) AR045999A1 (OSRAM)
AT (1) ATE370135T1 (OSRAM)
DE (1) DE602004008291T2 (OSRAM)
ES (1) ES2291913T3 (OSRAM)
TW (1) TW200514781A (OSRAM)
WO (1) WO2005014571A1 (OSRAM)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007010350A1 (en) * 2005-07-19 2007-01-25 Pfizer Products Inc. Synthesis of therapeutic diphenyl ethers
EP1909797A4 (en) 2005-08-02 2013-02-27 Neurogen Corp DIPIPERAZINYL KETONE AND RELATED ANALOG
WO2008145681A2 (en) 2007-05-31 2008-12-04 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
CA2700963A1 (en) * 2007-09-28 2009-04-09 Schering Corporation Oxypiperidine derivatives and methods of use thereof
MX2011005150A (es) 2008-12-19 2011-05-30 Boehringer Ingelheim Int Pirimidin-4-carboxamidas ciclicas como antagonistas del receptor ccr2 para el tratamiento de inflamacion, asma y epoc.
PH12012501215A1 (en) 2009-12-17 2015-11-13 Centrexion Therapeutics Corp New ccr2 receptor antagonists and uses thereof
EP2569295B1 (en) 2010-05-12 2014-11-19 Boehringer Ingelheim International GmbH New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
US8877745B2 (en) 2010-05-12 2014-11-04 Boehringer Ingelheim International Gmbh CCR2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
CN102260277B (zh) 2010-05-24 2013-07-24 中国科学院上海药物研究所 新型苯并噁嗪噁唑烷酮类化合物及其制备方法和用途
JP5636094B2 (ja) 2010-05-25 2014-12-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ccr2受容体アンタゴニスト
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
ES2823350T3 (es) 2010-07-29 2021-05-06 Rigel Pharmaceuticals Inc Compuestos heterocíclicos que activan AMPK y métodos de uso de los mismos
JP5786258B2 (ja) 2011-07-15 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規かつ選択的なccr2拮抗薬
CN104114538B (zh) * 2012-01-16 2016-04-13 葛兰素史克知识产权发展有限公司 治疗用途
EP2804853A4 (en) * 2012-01-16 2015-09-23 Glaxosmithkline Ip Dev Ltd THERAPEUTIC USES
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
EP2647377A1 (en) 2012-04-06 2013-10-09 Sanofi Use of an h3 receptor antagonist for the treatment of alzheimer's disease
MX383744B (es) 2015-07-02 2025-03-14 Centrexion Therapeutics Corp Citrato de (4-((3r,4r)-3-metoxitetrahidro-piran-4-ilamino)piperidin-1-il) (5-metil-6-(((2r, 6s)-6-(p-tolil)tetrahidro-2h-piran-2-il) metilamino) pirimidin-4-il) metanona.
EP3383853B1 (en) * 2015-12-01 2020-11-04 Merck Sharp & Dohme Corp. Homobispiperidinyl derivatives as liver x receptor (lxr) beta agonists for treating e.g. alzheimer's disease
CN116615417B (zh) * 2022-03-31 2024-05-14 广州必贝特医药股份有限公司 1,4-二杂环基取代芳环或芳杂环类化合物及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20020507A1 (es) * 2000-10-17 2002-06-25 Schering Corp Compuestos no-imidazoles como antagonistas del receptor histamina h3
CA2436083A1 (en) * 2001-02-08 2002-09-19 Schering Corporation Use of dual h3/m2 antagonists in the treatment of cognition deficit disorders
JP4563675B2 (ja) * 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンh3受容体関連疾患の治療のためのその使用
EP1552842A1 (en) * 2002-06-07 2005-07-13 Kyowa Hakko Kogyo Co., Ltd. Bicyclic pyrimidine derivatives

Also Published As

Publication number Publication date
ES2291913T3 (es) 2008-03-01
DE602004008291T2 (de) 2008-05-08
TW200514781A (en) 2005-05-01
DE602004008291D1 (de) 2007-09-27
EP1646620B1 (en) 2007-08-15
EP1646620A1 (en) 2006-04-19
JP2006528147A (ja) 2006-12-14
US20060247227A1 (en) 2006-11-02
WO2005014571A1 (en) 2005-02-17
AR045999A1 (es) 2005-11-23

Similar Documents

Publication Publication Date Title
ATE370135T1 (de) Substituierte piperidine als histamin-h3- rezeptorliganden
ZA200700683B (en) Piperidine derivatives as histamine H3 receptor ligands
ATE529112T1 (de) 1-(4-piperidinyl)benzimidazolone als histamin h3 antagonisten
ATE494285T1 (de) Muscarinische acetylcholin-rezeptor-antagonisten
ATE448217T1 (de) Substituierte piperidine als renin-inhibitoren
ATE450526T1 (de) Als antagonisten von histamin h3 geeignete piperidinderivate
ATE389406T1 (de) 1-(4-piperidinyl)benzimidazole als histamin h3 antagonisten
DE60137461D1 (de) Substituierte Piperidinverbindungen zur Verwendung als H3 Histaminerezeptorantagonisten
DK1682142T3 (da) M3-muscarin-acetylcholin-receptor-antagonister
DE60331751D1 (de) N-substituierte 2-oxodihydropyridinderivate als npy antagonisten
DK1515969T3 (da) Spiroindolinpiperidinderivater
ATE344798T1 (de) Als histamin-h3-antagonisten geeignete indolderivate
NO20053650D0 (no) Nedihullsverktoy
ATE414698T1 (de) Durch 5gliedrige heterocyclen substituierte mtp- inhibierende arylpiperidine oder -piperazine
ATE387202T1 (de) Pyrrolidinderivate als histaminrezeptor-liganden
DE60320529D1 (de) Chinolinderivate als npy antagonisten
DK1472256T3 (da) Piperidinderivater
DE60314170D1 (de) Substituierte 4-amino-1-(pyridylmethyl)piperidine zur verwendung als muscarinrezeptor-antagonisten
ATE479681T1 (de) Substituierte piperidine
DK1773810T3 (da) Hidtil ukendte 4-benzylidenpiperidinderivater
ATE364602T1 (de) 4-(aminomethyl)-piperidinbenzamide als 5ht4 - antagonisten
DE60316411D1 (de) Thiazolderivate als npy-rezeptorantagonisten
DE602004015610D1 (de) 3-fluoro-piperidine als nmda/nr2b antagonisten
ATE377008T1 (de) Imidazolderivate als glutamatrezeptorantagonisten
ATE471321T1 (de) Substituierte piperidine als renin-inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties